Lista de obras - Jan H Beumer - Dominio Público Uruguay

<i>ALDH1A1</i> Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and Copper

artículo científico publicado en 2022

A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.

artículo científico publicado en 2012

A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.

artículo científico publicado en 2009

A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum

scientific article published on 24 May 2006

A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay

artículo científico publicado en 2012

A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice

scientific article published on 01 October 2006

A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.

artículo científico publicado en 2015

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

scientific article published on 10 September 2013

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

scientific article published on 04 September 2019

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine

artículo científico publicado en 2015

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

artículo científico publicado en 2013

A phase i study of DMS612, a novel bifunctional alkylating agent

artículo científico publicado en 2014

A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.

artículo científico publicado en 2018

A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells

artículo científico publicado en 2015

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy

artículo científico publicado en 2014

ATM serine-1981 phosphorylation is a plausible biomarker

artículo científico publicado en 2015

ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage

artículo científico publicado en 2013

An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma.

artículo científico publicado en 2015

Body-surface area-based chemotherapy dosing: appropriate in the 21st century?

artículo científico publicado en 2012

CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells.

artículo científico publicado en 2012

Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers

artículo científico publicado en 2013

Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers

artículo científico publicado en 2013

Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).

artículo científico publicado en 2015

Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer.

artículo científico publicado en 2011

Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis.

artículo científico publicado en 2014

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma

artículo científico publicado en 2015

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

artículo científico publicado en 2007

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

artículo científico publicado en 2009

Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome

scientific article published on 01 July 2006

Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies

artículo científico publicado en 2015

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib

artículo científico publicado en 2009

Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).

artículo científico publicado en 2014

Effect of antacid on imatinib absorption

artículo científico publicado en 2008

Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice

artículo científico publicado en 2013

Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

scientific article published on 01 November 2016

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi

artículo científico publicado en 2018

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

artículo científico publicado en 2009

Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker

scientific article published on 18 September 2020

Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines

artículo científico publicado en 2012

Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma

artículo científico publicado en 2015

Halofuginone infused keratin hydrogel attenuates adhesions in a rodent cecal abrasion model

artículo científico publicado en 2012

Hepatotoxicity and metabolism of trabectedin: a literature review.

artículo científico publicado en 2005

Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation

artículo científico publicado en 2015

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

artículo científico publicado en 2016

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

artículo científico publicado en 2007

Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients.

artículo científico publicado en 2005

Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.

artículo científico publicado en 2009

In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization ⬇️

artículo científico publicado el 26 de agosto de 2010

In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction

scientific article published on 07 June 2015

In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine

scientific article published on 28 September 2020

LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.

artículo científico publicado en 2016

LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma

artículo científico publicado en 2013

LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma

artículo científico publicado en 2016

Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase

scientific article published on 31 July 2008

Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.

artículo científico publicado en 2010

Mass balance studies, with a focus on anticancer drugs.

artículo científico publicado en 2006

Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.

artículo científico publicado en 2008

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

artículo científico publicado en 2018

Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

artículo científico publicado en 2020

Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans

artículo científico publicado en 2015

Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice

scientific article published on 30 November 2006

Pharmacotherapy in cancer patients with HIV/AIDS

artículo científico publicado en 2014

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

artículo científico publicado en 2016

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

artículo científico publicado en 2016

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study

artículo científico publicado en 2010

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies

artículo científico publicado en 2016

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

artículo científico publicado en 2012

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer

artículo científico publicado en 2017

Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.

artículo científico publicado en 2012

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

artículo científico publicado en 2010

Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews

artículo científico publicado en 2014

Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs

artículo científico publicado en 2015

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.

artículo científico publicado en 2014

Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer

scientific article published on 27 May 2014

Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.

artículo científico publicado en 2015

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spe

artículo científico publicado en 2004

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.

artículo científico publicado en 2014

Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al.

artículo científico publicado en 2016

Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer

scientific article published on 02 August 2013

Role of histone deacetylases and their inhibitors in cancer biology and treatment.

artículo científico publicado en 2010

Targeting p53-dependent stem cell loss for intestinal chemoprotection.

artículo científico publicado en 2018

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment

artículo científico publicado en 2014

Therapeutic drug monitoring of 5-fluorouracil.

artículo científico publicado en 2016

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation

artículo científico publicado en 2016

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

artículo científico publicado en 2005

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia

artículo científico publicado en 2013

Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features

artículo científico publicado en 2016

VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells

artículo científico publicado en 2014

Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial

artículo científico publicado en 2013

Without therapeutic drug monitoring, there is no personalized cancer care

scientific article published on 01 March 2013

Lista de obras de Jan H Beumer

<i>ALDH1A1</i> Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and Copper

A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.

A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.

A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum

A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay

A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice

A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

A phase i study of DMS612, a novel bifunctional alkylating agent

A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.

A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy

ATM serine-1981 phosphorylation is a plausible biomarker

ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage

An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma.

Body-surface area-based chemotherapy dosing: appropriate in the 21st century?

CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells.

Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers

Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers

Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).

Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer.

Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis.

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome

Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib

Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).

Effect of antacid on imatinib absorption

Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice

Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker

Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines

Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma

Halofuginone infused keratin hydrogel attenuates adhesions in a rodent cecal abrasion model

Hepatotoxicity and metabolism of trabectedin: a literature review.

Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients.

Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.

In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization ⬇️

In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction

In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine

LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.

LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma

LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma

Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase

Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.

Mass balance studies, with a focus on anticancer drugs.

Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans

Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice

Pharmacotherapy in cancer patients with HIV/AIDS

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer

Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews

Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.

Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer

Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spe

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.

Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al.

Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer